Ultomiris brings more good news for AstraZeneca with NMOSD data

5 May 2022

Just a week on from the US Food and Drug Administration (FDA) granting approval for Ultomiris (ravulizumab-cwvz) in generalized myasthenia gravis (gMG), the long-acting C5 complement inhibitor has shown its promise in another potential indication.

First marketed to treat paroxysmal nocturnal hemoglobinuria in 2018, the product was developed by Alexion and became part of AstraZeneca’s (LSE: AZN) portfolio following the British firm’s $39 billion purchase of the rare disease specialist in 2021.

"Patients on Ultomiris remained relapse free over a median treatment duration of 73 weeks in the trial"The gMG approval was seen as the latest vindication of AstraZeneca’s Alexion acquisition, and there was further evidence of the buy being a smart move in the shape of new Ultomiris data being presented on Thursday.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK